Filing Flows › Comparisons › DRIO vs VVOS
DarioHealth vs Vivos Therapeutics: DRIO and VVOS compared
DarioHealth is the larger company: $5.2M of revenue in its latest quarter (Q2 2026) against $5.2M for Vivos Therapeutics (Q2 2026). Vivos Therapeutics is growing faster (+35% against -4% a year earlier). Vivos Therapeutics is more profitable, with an operating margin of -93.6% against -125.1%.
Where the money goes: DRIO and VVOS
DarioHealth (DRIO) · Q2 2026
DarioHealth, Q2 2026: revenue $5.2M (-4% year over year), operating margin -125.1%, net loss $7.9M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Vivos Therapeutics (VVOS) · Q2 2026
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| DarioHealth (DRIO) | Vivos Therapeutics (VVOS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5.2M | $5.2M |
| Revenue growth, Y/Y | -4% | +35% |
| Operating margin | -125.1% | -93.6% |
| Net earnings | −$7.9M | −$5.5M |
| Net margin | -153.1% | -107.2% |
| Operating cash flow | −$6.1M | −$3.1M |
Where the revenue comes from
DarioHealth
- Hardware and Consumable Products: $2.6M (50%)
- Services: $2.6M (50%)
Vivos Therapeutics
- Service: $3.8M (74%)
- Product: $1.4M (26%)
Questions
Which is bigger, DarioHealth or Vivos Therapeutics?
DarioHealth is the larger company: $5.2M of revenue in its latest quarter (Q2 2026) against $5.2M for Vivos Therapeutics (Q2 2026).
Is DarioHealth or Vivos Therapeutics growing faster?
Vivos Therapeutics is growing faster (+35% against -4% a year earlier).
Which is more profitable, DarioHealth or Vivos Therapeutics?
Vivos Therapeutics is more profitable, with an operating margin of -93.6% against -125.1%.
More: DarioHealth earnings · how DarioHealth makes money · Vivos Therapeutics earnings · how Vivos Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.